Dupilumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Dupilumab |
| DrugBank ID | DB12159 |
| Brand Names (EU) | Dupixent |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.92% |
Approved Indication (EMA)
Atopic dermatitis Adults and adolescentsDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Children 6 months to 11 years of ageDupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. Asthma Adults and adolescentsDupixent is indicated in adults and adolescents 12 years and older as add-on mainte
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | bronchitis | 99.92% | DL |
| 2 | dermatitis | 99.71% | DL |
| 3 | acne keloid | 99.61% | DL |
| 4 | exanthem (disease) | 99.57% | DL |
| 5 | neonatal dermatomyositis | 99.56% | DL |
| 6 | acrodermatitis chronica atrophicans | 99.54% | DL |
| 7 | amyopathic dermatomyositis | 99.53% | DL |
| 8 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | 99.52% | DL |
| 9 | hydroa vacciniforme, familial | 99.50% | DL |
| 10 | atopic eczema | 99.28% | DL |
| 11 | severe nonproliferative diabetic retinopathy | 99.10% | DL |
| 12 | postinfectious vasculitis | 98.76% | DL |
| 13 | post-bacterial disorder | 98.75% | DL |
| 14 | infective urethral stricture | 98.74% | DL |
| 15 | post-infectious syndrome | 98.73% | DL |
| 16 | infection-related hemolytic uremic syndrome | 98.71% | DL |
| 17 | Chagas cardiomyopathy | 98.69% | DL |
| 18 | otitis externa | 98.41% | DL |
| 19 | pityriasis simplex | 98.24% | DL |
| 20 | bronchial neoplasm (disease) | 98.19% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.